BioMedNewsBreaks Archive - Page 127 of 129

WednesdaySep 25, 2019 10:48 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Highlighted in Editorial on Potential Breast Cancer Treatments

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its placement in an editorial published by BioMedWire ("BMW"), a multifaceted financial news and publishing company for private and public entities. The publication, titled “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers,” may be accessed via the following link: http://nnw.fm/pNKm2. The editorial reads,“‘Disruptive’ isn’t a term that’s often applied to medicine, where the aim is to avoid disrupting the health of the human body. But technology such as Genprex Inc.’s (NASDAQ: GNPX) Oncoprex(TM) immunogene therapy is disruptive precisely because it could improve doctors’ ability to preserve health. It may…

WednesdaySep 18, 2019 10:22 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) CEO to Present Via Webcast at September 19 Singular Research Midwestern Values Conference

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will present, via webcast, at the Singular Research Midwestern Values Conference on September 19, 2019. Genprex Chairman and CEO Rodney Varner will lead the company's webcast presentation. The presentation is scheduled to begin at 4:00 PM Central Time, and interested parties may register for the webcast via the Singular Research website. To view the full press release, visit http://nnw.fm/IxlP7 About Genprex, Inc. Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial…

WednesdaySep 11, 2019 10:17 am

BioMedNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) TUSC2 Found to Prevent Tumor Growth in Triple-Negative Breast Cancer by Independent Researchers

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that non-affiliated, independent researchers have reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, prevented tumor growth in triple-negative breast cancer (“TNBC”). Currently considered an incurable cancer, there are limited therapeutic options available for TNBC. “The results of the study evaluating TUSC2 for the treatment of triple-negative breast cancer are encouraging,” Genprex Chairman and CEO Rodney Varner said in the news release. “We believe that the data reported in this Nature article by independent researchers supports our belief that…

ThursdaySep 05, 2019 9:19 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Corporate Update; Set to Present at H.C. Wainwright 21st Annual Global Investment Conference

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Tuesday issued an update regarding its clinical development programs, manufacturing and strategy for bringing its Oncoprex(TM) immunogene therapy to market. A corporate presentation is available on GNPX’s website which details anticipated milestones and future guidance for the company. “These milestones emphasize our commitment to developing potentially life-changing gene technologies for cancer patients who need them most,” Genprex chairman and chief executive officer Rodney Varner stated in the news release. “We continue to dedicate our efforts toward developing Oncoprex for non-small cell lung cancer (“NSCLC”) and we believe that achievement of these milestones…

WednesdayAug 21, 2019 10:12 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Chairman and CEO to Present at the 4th Annual Disruptive Growth Conference

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that its Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference. ReedSmith is hosting the event, which features growth companies with disruptive technologies and business models across a variety of sectors, at its offices at 599 Lexington Avenue in New York City on September 4, 2019. The Genprex presentation is slated for 5:00 p.m. to 5:15 p.m. Eastern Time in Presentation Room A/B. To view the full press release, visit http://nnw.fm/oGep8 About Genprex, Inc. Genprex, Inc. is a clinical stage gene…

TuesdayAug 13, 2019 9:59 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Recent Achievements as Part of Overall Expansion Strategy

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its recent achievements as part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex(TM) immunogene therapy, to commercialization. Per the update, Genprex has published recent as well as historical achievements to its newly launched, interactive corporate timeline, which can be found on the company’s website. “Since Genprex’s IPO last year, we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research, our manufacturing process development and scalability, and the growth…

TuesdayAug 06, 2019 11:02 am

BioMedNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Manufacturing Partner Aldevron Completes Significant Manufacturing Step for Initial Product Candidate, Oncoprex(TM)

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA per the manufacturing agreement between the companies that was disclosed in September 2018. According to the update, Genprex’s Oncoprex(TM), the company’s initial product candidate, consists of a TUSC2 plasmid DNA manufactured by Aldevron encapsulated in a nanovesicle made from lipid molecules with a positive electrical charge. Historically, manufacturing steps have been done for Genprex at MD Anderson Cancer Center, but, since Genprex’s IPO, the company has been working to transfer and…

WednesdayJul 31, 2019 10:37 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Initiates First Phase of Branding Lead Drug Candidate

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced it has initiated the first phase of branding its lead drug candidate, Oncoprex(TM) immunogene therapy, and has completed and submitted non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (“USAN”) Council. According to the update, Genprex will, upon receipt of USAN feedback expected later this year, submit its non-proprietary drug name selections to the World Health Organization for International Nonproprietary Names (“INN”) status. By mid-2020, the company expects to obtain an approved non-proprietary drug name. “Developing and obtaining regulatory approval of a non-proprietary drug name is…

MondayJul 01, 2019 10:33 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Provides Update on Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning provided an update on the development of its lead drug candidate, Oncoprex(TM) immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (“NSCLC”). Based on data from the ongoing study through GNPX’s July 2018 sponsored research agreement with The University of Texas MD Anderson Cancer Center, as well as prior clinical and pre-clinical studies, Genprex is working with its scientific advisory board and outside consultants to design a clinical trial for Oncoprex. According to the update, the new study will focus on Oncoprex in combination with…

TuesdayJun 11, 2019 12:33 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Advances Toward Lead Drug Candidate Commercialization through Retaining Addison Whitney to Oversee Naming Process

Genprex (NASDAQ: GNPX), a clinical-stage, gene-therapy company, recently announced that it has retained pharmaceutical branding agency Addison Whitney to assist with the naming of the company’s leading drug candidate (http://nnw.fm/4arQW). An article further discussing the company reads, “Addison Whitney has a proven track record of branding success within the pharmaceutical market. It enables clients to achieve growth through both brand differentiation and creative naming practices. Its most recent successes include guiding pharmaceutical companies such as Merck, Celgene and Roche through the regulatory steps needed for name approval. . . . According to Genprex Chairman and CEO Rodney Varner, retaining the services…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

BioMedNewsBreaks